MoneyWorks4Me

USFDA concludes inspection at Lupin’s Nagpur facility with no observations

14 May 2018 Evaluate

Lupin has successfully completed an inspection carried out by the US Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations. The company’s Nagpur facility is the latest facility and manufactures oral solid products.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..